Citations

Clear

21 citation(s) found for "Nguyen, Linda A".

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
A, Prera Vilaseca, Bilodeau, Philippe, Gakis, Georgios , Savransky, Andrea, Oliveira, Joao Mahler Ferreira, Nguyen, Linda, Hooshmand, Sam I., Satyanarayan, Sammita , Moseley, Carson E., Haley, Leah , Roy-Hewitson, Chantal, Marrodan, M, Casallas, Adriana, Manín, Analisa , Chen, H, Grzezulkowska, Aniela, Contentti, Edgar Carnero, Galleguillos, Lorna, Upchurch, Margaret, Jackson-Tarlton, Caitlin S. , Guo, Joanne Chu-Yueh, Fabian, Michelle, Caparó-Zamalloa, César, Paterno, R, Waubant, Emmanuelle, Boschetti, Laura Ordoñez, Correale, Jorge, Villa, Andrés M., Banwell, Brenda, Marignier, Romain, Pittock, Sean J., Greenberg, Benjamin , Bennett, Jeffrey L., Cho, Tracey, Clardy, Stacey, Solomon, Andrew J., Ja, Gelfand, Obeidat, Ahmed Z., Blackburn, Kyle, Tenembaum, Silvia , Chen, John J., Sotirchos, Elias S., Levy, Michael, Flanagan, Eoin P., Group, and The Americas MOGAD Treatment, Murillo, Fabian, Syc-Mazurzek, Stephanie B., Jiang, Mulan , Rezende, N, Wingerchuk, D M, Horsman, Susan E. , Bilodeau, Philippe‐Antoine , Bilodeau, Philippe A , Vilaseca, Andreu , Hooshmand, Sam , Moseley, Carson E. , Marrodán, Mariano , Vanegas, Adriana Casallas , Hoshina, Yoji , Contentti, Edgar Carnero , Galleguillos, Lorna , Virupakshaiah, Akash , Arrambide, Georgina , Caparó‐Zamalloa, César , Waubant, Emmanuelle L. , Ordóñez-Boschetti, Laura, Villa, Andres Maria , Marignier, Romain , Pittock, Sean J. , Bennett, Jeffrey L. , Cho, Tracey , Clardy, Stacey , Solomon, Andrew , Kister, Ilya , Zamvil, Scott S. , Gelfand, Jeffrey M. , Repovic, Pavle , Obeidat, Ahmed Zayed , Blackburn, Kyle , Chen, John J., Sotirchos, Elias S. , Levy, Michael , Flanagan, Eoin P. , Syc‐Mazurek, Stephanie B. , Cacciaguerra, Laura , Rezende, Nathane Braga da Silva, Wingerchuk, Dean M.

Mayo Clinic

JAMA Neurology | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2220 | PMID 42440328 Get It

Importance Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) lacks proven relapse-preventive therapies. While clinical trials are ongoing, safety data may be limited and approved drugs are costly. Studies of interleukin 6 receptor blocker (IL-6RB) in MOGAD are limited by small numbers and no comparative studies, contributing to low use. Objective To evaluate the impact of IL-6RB therapy on relapse rates in MOGAD and compare relapse frequency with intravenous immunoglobulin (IVIG). Design, Setting, and Participants This international, multicenter, retrospective cohort study (January 1, 2015, through December 31, 2025) included a historical IVIG-treated cohort of varying doses. The study took place across sites in North and South America (US, Canada, Mexico, Argentina, Brazil, Chile, Colombia, and Peru). Patients with MOGAD (n = 116, no excluded patients) who received at least 1 dose of an IL-6RB were included. These data were analyzed in January 2026. Exposures Tocilizumab or satralizumab. Main Outcomes and Measures Annualized relapse rate (ARR) during IL-6RB therapy, time to next relapse after treatment initiation, and adverse events. Outcomes were compared with the IVIG cohort using inverse probability of treatment weighting (IPTW) adjusted for age, sex, prior ARR, and concomitant therapies. Results A total of 116 patients with MOGAD (89% relapsing) receiving IL-6RB (tocilizumab, 104 [90%] and satralizumab, 12 [10%]) were included; overall, 60.3% were female, 39.7% were male, and 18% were younger than 18 years. The median (IQR) IL-6RB treatment follow-up was 1.4 (0.7-2.5) years and 23 relapses occurred during 241.8 person-years of IL-6RB therapy. The ARR decreased from 0.64 (95% CI, 0.58-0.70) for relapsing MOGAD before IL-6RB to 0.09 (95% CI, 0.06-0.14) during IL-6RB treatment (incidence rate ratio, 0.08; 95% CI, 0.04-0.16). Adverse events occurred in 58 patients (50%), most commonly mild infections, although 10 (9%) had severe infections. In the IVIG cohort (n = 59), 30 relapses occurred over 133.8 person-years (ARR, 0.22; 95% CI, 0.15-0.32). After IPTW, IL-6RB was associated with a lower hazard ratio (HR) than the group who underwent IVIG therapy less than 1 g/kg every 4 weeks (HR, 4.5; 95% CI, 2.0-9.8), with no significant difference vs the group who underwent IVIG 1 g/kg or more every 4 weeks (HR, 2.0; 95% CI, 0.8-4.5). Conclusions and Relevance In this multicenter observational cohort, IL-6RB use in MOGAD was associated with low relapse rates and a favorable safety profile, though severe infections occurred occasionally. Relapse rates were lower than the group who underwent IVIG less than 1 g/kg every 4 weeks but not significantly different from the group who underwent IVIG 1 g/kg or more every 4 weeks. This supports IL-6RB as a potential relapse-prevention therapy in MOGAD; the wide availability and relative affordability of tocilizumab may enable broad global use.
Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: ‘Auckland Classification’ v1.0
Varghese, Chris , Dachs, Nicky , Schamberg, Gabriel , Abell, Thomas, Al‐Haddad, Mohammad, Angeli, Timothy R. , Ayubi, Homira , Bashashati, Mohammad , Bulat, Robert, Calder, Stefan, Cederwall, Christopher Brian, Chang, Bianca W. , Cheng, Leo K. , Clarke, John, Daker, Charlotte , Du, Peng, Erickson, Jon, Eriksson, Sven, Fikree, Asma , Foong, Daphne , Fox, Mark, Goenka, Mahesh, Haidry, R, Holtman, Gerald, Hobson, Anthony , Koloski, Natasha, Kuo, Braden, Law, Mikaela, Levinthal, D., Liu, Joy , Mathur, Prateek , Moshiree, Baharak, Ngo, Catherine, Nguyen, Linda, Oblizajek, Nicholas R. , Parkman, Henry P., Podboy, Alexander, Rezaie, Ali, Simmonds, Sam , Sivakumar, Jonathan , Sirimongkolkasem, Jarongkorn , Sonu, Irene, Stocker, Abigail, Sujka, Joseph, Tack, Jan, Weinstein, Douglas, Windsor, John, Zarate‐Lopez, Natalia, Andrews, Christopher N., O'Grady, Greg, Clarke, John O. , Angeli-Gordon, Timothy R , Chang, Bianca , Cheng, Leo K , Daker, Charlotte , Ghoshal, Uday C , Hasler, W L , Ho, Vincent , Keszthelyi, Daniel , Khalsa, Sahib S , Liu, Joy J , Neshatian, Leila , Oblizajek, Nicholas R , Pandanaboyana, Sanjay , Sharma, Amol , Wang, Xiao Jing , Xu, William , Varghese, Chris , Clarke, J , Schamberg, Gabriel , Al‐Haddad, Mohammad , Ayazi, Shahin , Bulat, Robert, Calder, Stefan , Cederwall, Chris, Du, Peng , Erickson, Jonathan C. , Ghoshal, Uday C. , Hasler, William L. , Hayee, Bu , Ho, Vincent , Huang, I‐Hsuan , Khalsa, Sahib S. , Kuo, Braden , Kunkel, David C. , Law, Mikaela , Levinthal, David J. , Moshiree, Baharak , Neshatian, Leila , Parkman, Henry P. , Podboy, Alexander , Rezaie, Ali , Sonu, Irene S. , Stocker, Abigail, Sujka, Joseph , Tack, Jan , Verdonk, Charles , Wang, Xiao Jing , Wongjarupong, Nicha , Xu, William , Andrews, Christopher N. , Gharibans, Armen A.

Mayo Clinic

Neurogastroenterology & Motility | July 1, 2026 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/nmo.70377 | PMID 42381563 Get It

ABSTRACT Introduction Chronic gastroduodenal disorders remain challenging to manage, and new diagnostic approaches are needed to better delineate underlying causes and guide therapeutic decisions. Body Surface Gastric Mapping (BSGM) technologies combine high‐resolution gastric myoelectrical activity measurements with symptom and psychological profiling to provide mechanistic insights into gastric motor and sensory dysfunction. An International Working Group convened to derive the first consensus classification of BSGM phenotypes (the “Auckland Classification”). Methods A Technical Group conducted a systematic literature and clinical database review to identify objective test biomarkers and candidate disease mechanisms. Evidence was synthesized across 50 studies (primarily in gastroparesis, chronic nausea and vomiting, and functional dyspepsia), and BSGM phenotypes were mapped to existing treatment guidelines. Subsequently, iterative review and development of consensus was performed by a Consensus Group composed of international clinical experts familiar with BSGM. Eleven statements underlying the classification were then derived and circulated as a final survey to establish agreement. Results Six BSGM phenotypes were endorsed: three defined by myoelectrical abnormalities (Dysrhythmic, High Frequency, and Low Meal Response) and three by characteristic symptom associations (Sensorimotor, Continuous, and Delayed Onset Symptoms). Published studies plausibly linked these phenotypes to mechanisms including interstitial cell of Cajal depletion, vagal impairment, hypomotility, visceral hypersensitivity, gut‐brain dysregulation, and small bowel dysfunction. Phenotypes were also mapped to existing mechanism‐based treatment guidelines. Ten out of the eleven statements had > 80% agreement. Conclusions The Auckland Classification, derived by international consensus, presents a structured framework for BSGM‐defined patient phenotypes. Evidence and mechanism‐based treatment options are suggested for each phenotype to provide a foundation for research, further validation, and a pathway for integrating BSGM into clinical care.
Autonomic Dysfunction in Gastroduodenal Disorders Evaluated Through Multimodal Non-Invasive Physiological Testing
Varghese, Chris , Zhou, Wendy , Schamberg, Gabriel , Hove, Sibylle Van, Clarke, John, O’Grady, G., Neshatian, Leila , Nguyen, Linda, Clarke, John O. , Varghese, Chris , Gharibans, Armen A , Schamberg, Gabriel , Van Hove, Sibylle , O'Grady, Gregory , Neshatian, Leila , Clarke, J , Gharibans, Armen A. , Nguyen, Linda Anh B.

Mayo Clinic

American Journal of Gastroenterology | February 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000003958 | PMID 41677129 Get It

INTRODUCTION: Chronic gastroduodenal disorders are highly prevalent and encompass heterogeneous pathophysiology. Autonomic dysfunction may contribute, but its relative contribution to disease pathophysiology and symptoms is unclear. This study aimed to clarify the contributions of autonomic dysfunction in gastroduodenal disorders and symptom associations using multimodal testing, hypothesizing that distinct disorder subgroups would be revealed. METHODS: This prospective observational cohort study included 80 patients with chronic gastroduodenal symptoms. Participants underwent expert clinician-led autonomic evaluation, body surface gastric mapping (BSGM; Gastric Alimetry, New Zealand), and gastric emptying scintigraphy testing. BSGM phenotyping, gastric emptying cutoffs, and autonomic criteria followed standard criteria. RESULTS: Gastroparesis was diagnosed in 27 (33.8%) patients. Autonomic dysfunction was present in 21 (26.3%) patients, and abnormal BSGM in 20 (25%). Autonomic dysfunction and abnormal BSGM were both more prevalent in gastroparesis (51.9% vs 13.2%, P = 0.001; and 44.4% vs 15.1%, P = 0.005, respectively). However, these diagnoses tended not to overlap, with patients having autonomic dysfunction generally exhibiting normal BSGM tests. Autonomic dysfunction independently predicted delayed gastric emptying (OR 13.8, P < 0.001) and was associated with earlier meal responses (higher meal response ratio, P = 0.04) and worse postprandial distress symptoms ( P < 0.05). DISCUSSION: Autonomic dysfunction independently predicted delayed gastric emptying and revealed a gastroparesis mechanism distinct from gastric myoelectrical impairment. Autonomic dysfunction altered the postprandial gastric motor response and was associated with a greater symptom burden. Multimodal physiological testing including autonomic profiling reveals distinct mechanistic subgroups in patients with chronic gastroduodenal symptoms.
American College of Gastroenterology Monograph on Geriatrics and GI
Kane, Sunanda V. , Gardner, Timothy B. , Shaheen, Nicholas J. , Brown, Cristal , Bajaj, Jasmohan S. , Lutz, Megan , Caldera, Freddy, Shaukat, Aasma, Faye, Adam S , Calderwood, Audrey H. , Kochar, Bharati D. , Katz, Seymour , Lee, Linda , Yadlapati, Rena , Wang, Xiao Jing , Nguyen, Linda Anh B. , Caldera, Freddy

Mayo Clinic

American Journal of Gastroenterology | October 3, 2025 | Volume: 120 | Issue: 10S | Pages: S6-S6

10.14309/ajg.0000000000003641 | PMID 41041992 Get It

Late Relapse After Autologous Hematopoietic Stem Cell Transplantation in AQP4-IgG–Positive NMOSD
Vorasoot, Nisa , Bush, Melissa L., Jenkins, Sarah M. , Jitprapaikulsan, Jiraporn , Fryer, James P., Irani, Sarosh R. , Pittock, Sean J. , Pittock, S J , Irani, Sarosh R , Vorasoot, Nisa , Blackburn, Kyle , Nguyen, Linda , Bush, Melissa L., Flanagan, Eoin P.

Mayo Clinic

JAMA Network Open | April 21, 2025 | Volume: 8 | Issue: 4 | Pages: e255989

10.1001/jamanetworkopen.2025.5989 | PMID 40257801 Get It

This case series examines long-term outcomes for 2 aquaporin-4-IgG (AQP4-IgG)–positive patients with neuromyelitis optica spectrum disorder (NMOSD) who underwent autologous hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen and rituximab.
Impact of Constipation Therapies on Severity of Gastroparesis and Constipation Symptoms in Relation to Gastric and Colonic Transit
Surjanhata, Brian , Moshiree, Baharak , Lee, Allen , McCallum, Richard W. , Sarosiek, Irene , Nguyen, Linda Anh B. , Schulman, Michael I., Wo, John M. , Parkman, Henry P. , Surjanhata, Brian C , Nguyen, Linda A , Hasler, William L. , Rao, Satish , Parkman, H P , Lee, Allen A , Kuo, Braden , Rao, Satish S.C.

Mayo Clinic

Neurogastroenterology & Motility | March 11, 2025 | Volume: 37 | Issue: 6 | Pages: No page available

10.1111/nmo.70013 | PMID 40033166 Get It

ABSTRACTIntroductionStudies demonstrate an overlap of constipation with gastroparesis and functional dyspepsia, but the impact of treatments that target constipation on improving upper gastrointestinal (UGI) symptoms is unexplored. We quantified the effects of constipation medication therapies on UGI and constipation symptom severity in subjects presenting with symptoms of gastroparesis.MethodsFifty‐six subjects with symptoms of gastroparesis underwent concurrent wireless motility capsule and gastric emptying scintigraphy and were recommended to receive either a new medication therapy for constipation or a change in constipation therapy based on investigator interpretation of test results. Gastroparesis Cardinal Symptom Index (GCSI), upper abdominal pain, and constipation scores were compared between baseline and 6 months. Data were compared between delayed or non‐delayed gastric emptying and the presence or absence of slow colonic transit.Key ResultsSubjects with slow colonic transit had improvements in GCSI (p = 0.007) and constipation scores (p = 0.004) after treatment with a new or changed constipation medication, with the delayed emptying subgroup driving GCSI improvements (p = 0.004). Reductions in nausea/vomiting (p = 0.02) and early satiety/fullness subscores (p = 0.002) with trends to improved bloating/distention subscores (p = 0.06) were observed in this subgroup, but upper abdominal pain was unchanged. Subjects with normal colonic transit showed no improvement in GCSI scores regardless of gastric emptying status (p > 0.05).Conclusions and InferencesIdentifying and treating delayed colonic transit in gastroparetic (delayed gastric emptying) subjects improves global UGI symptoms as well as selected individual symptoms. Evaluation of whole gut motility as well as recognizing and managing extragastric delay may promote improved outcomes in these patients.Trial RegistrationClinicalTrials.gov: NCT02022826
Predicting Response to Neuromodulators or Prokinetics in Patients With Suspected Gastroparesis Using Machine Learning: The “BMI, Infectious Prodrome, Delayed GES, and No Diabetes” Model
Takakura, Will , Surjanhata, Brian , McCallum, Richard W. , Schulman, Michael I., Wo, John M. , Sarosiek, Irene , Moshiree, Baha , Lee, Allen , Hasler, William L. , Lee, Allen A , Nguyen, Linda Anh B. , Parkman, Henry P. , Rao, Satish S.C. , Kuo, Braden

Mayo Clinic

Clinical and Translational Gastroenterology | July 8, 2024 | Volume: 15 | Issue: 9 | Pages: e1

10.14309/ctg.0000000000000743 | PMID 39320959 Get It

INTRODUCTION: Pharmacologic therapies for symptoms of gastroparesis (GP) have limited efficacy, and it is difficult to predict which patients will respond. In this study, we implemented a machine learning model to predict the response to prokinetics and/or neuromodulators in patients with GP-like symptoms. METHODS: Subjects with suspected GP underwent simultaneous gastric emptying scintigraphy (GES) and wireless motility capsule and were followed for 6 months. Subjects were included if they were started on neuromodulators and/or prokinetics. Subjects were considered responders if their GP Cardinal Symptom Index at 6 months decreased by ≥1 from baseline. A machine learning model was trained using lasso regression, ridge regression, or random forest. Five-fold cross-validation was used to train the models, and the area under the receiver operator characteristic curve (AUC-ROC) was calculated using the test set. RESULTS: Of the 150 patients enrolled, 123 patients received either a prokinetic and/or a neuromodulator. Of the 123, 45 were considered responders and 78 were nonresponders. A ridge regression model with the variables, such as body mass index, infectious prodrome, delayed gastric emptying scintigraphy, no diabetes, had the highest AUC-ROC of 0.72. The model performed well for subjects on prokinetics without neuromodulators (AUC-ROC of 0.83) but poorly for those on neuromodulators without prokinetics. A separate model with gastric emptying time, duodenal motility index, no diabetes, and functional dyspepsia performed better (AUC-ROC of 0.75). DISCUSSION: This machine learning model has an acceptable accuracy in predicting those who will respond to neuromodulators and/or prokinetics. If validated, our model provides valuable data in predicting treatment outcomes in patients with GP-like symptoms.
Hyperemesis Gravidarum and Nutritional Support
Elkins, Jaclyn R., Nguyen, Linda Anh B., Oxentenko, Amy S.

Mayo Clinic

American Journal of Gastroenterology | October 4, 2022 | Volume: 117 | Issue: 10S | Pages: 2-9

10.14309/ajg.0000000000001957 | PMID 36194027 Get It

ACG Clinical Guideline: Gastroparesis
Camilleri, Michael , Vaughn, Vida, Petrey, Jessica , Greer, Katarina B. , Kuo, Braden , Nguyen, Linda Anh B. , Yadlapati, Rena , Abell, Thomas L.

Mayo Clinic

American Journal of Gastroenterology | August 4, 2022 | Volume: 117 | Issue: 8 | Pages: 1197-1220

10.14309/ajg.0000000000001874 | PMID 35926490 Get It

Gastroparesis is characterized by symptoms suggesting retention of food in the stomach with objective evidence of delayed gastric emptying in the absence of mechanical obstruction in the gastric outflow. This condition is increasingly encountered in clinical practice. These guidelines summarize perspectives on the risk factors, diagnosis, and management of gastroparesis in adults (including dietary, pharmacological, device, and interventions directed at the pylorus), and they represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation process. When the evidence was not appropriate for Grading of Recommendations, Assessment, Development, and Evaluation, we used expert consensus to develop key concept statements. These guidelines should be considered as preferred but are not the only approaches to these conditions.
Plastic Drape and Copper Frame For Airway Management in the COVID-19 Era: A Case Series
Mainville, Darcy J., Hou, Borin, Chrissian, Ara A., Giri, Paresh C. , Chang, Melody , Turay, David, Shipley, Desara, Markovich, Susan, Scott, Loreen, Smith, Dustin D. , Dorotta, Ihab, Nguyen, H. Bryant , Mukherjee, Kaushik , Mainville, Darcy J

Mayo Clinic

No container title available | November 6, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-99957/v1 Get It

Abstract Purpose: Airway manipulation is a high-risk procedure due to aerosolization of viral particles. This has become of paramount importance during the COVID-19 pandemic in an effort to protect personnel involved in airway management. We designed and tested a copper frame to support a plastic drape to contain aerosols and allow for reduction of risk during airway management. The “CopperHead” frame allows airway management with minimal limitations in a wide range of scenarios including elective and urgent intubations, management of unstable patients, cardiopulmonary resuscitation (CPR), bronchoscopy, and extubation. The frame was made of copper to utilize its inherent antimicrobial and antiviral properties. Intervention and Measurements: We performed multiple simulations to measure FiO2 accumulation underneath the frame and plastic drape. We also performed defibrillations on a mannequin with the apparatus in place to evaluate for safety during times that the device is not removed prior to defibrillation, as indicated. We then deployed the device throughout our hospital and analyzed the resulting data on procedure success and infection rates in both COVID-positive and COVID-negative cohorts.Main Results: The technique is reproducible and allows for airway manipulation in COVID-19 suspected or confirmed patients. The FiO2 under the copper frame and plastic drape increased, but quickly dispersed when the frame was removed. We performed multiple defibrillations with apparatus in place with no adverse events. We showed that with the device in place, there appears to be no hindrance to successful intubation with 94 successful procedures in 74 patients and an 87% (60/69) first-pass intubation rate, and there were no documented clinicians or respiratory therapy infections through exposures to COVID-19 positive patients.Conclusions: The addition of a copper frame to a plastic drape over patients was an effective way to improve the safety and ease of intubation in the COVID-19 pandemic. This device was well received among our clinicians and served to benefit both intubation and extubation of recovered patients.